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A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is 
needed to control the coronavirus disease 2019 (COVID-19) global pandemic. 
Structural studies have led to the development of mutations that stabilize 
Betacoronavirus spike proteins in the prefusion state, improving their expression and 
increasing immunogenicity1. This principle has been applied to design mRNA-1273, an 
mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the 
prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing 
antibody responses to both wild-type (D614) and D614G mutant2 SARS-CoV-2 as well 
as CD8+ T cell responses, and protects against SARS-CoV-2 infection in the lungs and 
noses of mice without evidence of immunopathology. mRNA-1273 is currently in a 
phase III trial to evaluate its efficacy.
Since its emergence in December 2019, SARS-CoV-2 has accounted for 
more than 30 million cases of coronavirus disease 2019 (COVID-19) 
worldwide in 9 months3. SARS-CoV-2 is the third novel Betacoronavirus 
in the past 20 years to cause substantial human disease; however, unlike 
its predecessors SARS-CoV and Middle East respiratory syndrome 
coronavirus (MERS-CoV), SARS-CoV-2 is transmitted efficiently from 
person to person. In the absence of a vaccine, public health measures 
such as quarantine of newly diagnosed cases, contact tracing, use of 
face masks and physical distancing have been put into place to reduce 
transmission4. It is estimated that until 60–70% of the population have 
immunity, COVID-19 is unlikely to be sufficiently well-controlled for 
normal human activities to resume. If immunity remains solely depend-
ent on infection, even at a case fatality rate of 1%, more than 40 million 
people could succumb to COVID-19 globally5. Therefore, rapid develop-
ment of vaccines against SARS-CoV-2 will be critical for changing the 
global dynamics of this virus.
The spike (S) protein, a class I fusion glycoprotein analogous to 
influenza haemagglutinin, respiratory syncytial virus (RSV) fusion 
glycoprotein (F) and human immunodeficiency virus gp160 (Env), 
is the major surface protein on the coronavirus virion and the pri-
mary target for neutralizing antibodies. S proteins undergo marked 
structural rearrangement to fuse virus and host cell membranes, 
enabling delivery of the viral genome into target cells. We previously 
showed that prefusion-stabilized protein immunogens that preserve 
neutralization-sensitive epitopes are an effective vaccine strategy 
for enveloped viruses such as RSV6–10. Subsequently, we identified 2 
proline substitutions (2P) at the apex of the central helix and heptad 
repeat 1 that effectively stabilized MERS-CoV, SARS-CoV and human 
coronavirus HKU1 S proteins in the prefusion conformation1,11,12. Similar 
to other prefusion-stabilized fusion proteins, MERS-CoV S(2P) protein 
was more immunogenic at lower doses than wild-type S protein1. The 
2P mutation has similar effects on the stability of S proteins from other 
betacoronaviruses, suggesting a generalizable approach for designing 
stabilized-prefusion Betacoronavirus S protein antigens for vaccina-
tion. Such generalizability is fundamental to the prototype pathogen 
approach for pandemic preparedness13,14.
Coronaviruses have long been predicted to have a high probability of 
causing zoonotic disease and pandemics15,16. As part of our pandemic 
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preparedness efforts, we have studied MERS-CoV as a prototype 
Betacoronavirus pathogen to optimize vaccine design, dissect the 
humoral immune response to vaccination, and identify mechanisms 
and correlates of protection. Achieving an effective and rapid vac-
cine response to a newly emerging virus requires both the precision 
afforded by structure-based antigen design and a manufacturing 
platform to shorten time to product availability. Producing cell lines 
and clinical-grade subunit protein typically takes more than one year, 
whereas manufacturing nucleic acid vaccines can be achieved in a mat-
ter of weeks17,18. In addition to advantages in manufacturing speed, 
mRNA vaccines are potently immunogenic and elicit both humoral 
and cellular immunity19–21. We therefore evaluated mRNA formulated 
in lipid nanoparticles (mRNA–LNP) as a delivery vehicle for MERS-CoV 
S(2P), and found that transmembrane-anchored MERS-CoV S(2P) mRNA 
elicited more potent pseudovirus-neutralizing antibody responses 
than secreted MERS-CoV S(2P) (Extended Data Fig. 1a). Additionally, 
consistent with protein immunogens, MERS-CoV S(2P) mRNA was 
more immunogenic than wild-type MERS-CoV S mRNA (Extended Data 
Fig. 1b). Immunization with MERS-CoV S(2P) mRNA–LNP elicited potent 
pseudovirus-neutralizing activity with a dose as low as 0.1 μg and pro-
tected transgenic mice expressing human DPP4 (288/330+/+)22 against 
lethal MERS-CoV challenge in a dose-dependent manner, establishing 
that mRNA encoding S(2P) protein is protective. Notably, a subprotec-
tive 0.01 μg dose of MERS-CoV S(2P) mRNA did not cause exaggerated 
disease following MERS-CoV infection, but instead resulted in par-
tial protection against weight loss followed by full recovery without 
evidence of enhanced illness (Fig. 1).
SARS-CoV-2 was first identified as the cause of an outbreak of res-
piratory disease in Wuhan, China in early January 2020. Within 24 h of 
the release of genomic sequences of SARS-CoV-2 isolates on 10 Janu-
ary 2020, the 2P mutations were substituted into S protein residues 
986 and 987 to produce prefusion-stabilized SARS-CoV-2 S(2P) pro-
tein for structural analysis23 and serological assay development24,25 
in silico, without additional experimental validation. Within 5 days 
of the release of the sequence, current good manufacturing practice 
(cGMP) production of mRNA–LNP encoding the SARS-CoV-2 S(2P) as 
a transmembrane-anchored protein with the native furin cleavage 
site (mRNA-1273) was initiated in parallel with preclinical evaluation. 
This led to a first-in-human phase I clinical trial starting on 16 March 
2020, 66 days after the viral sequence was released, and a phase II trial 
74 days later on 29 May 2020 (Extended Data Fig. 2). Expression and 
antigenicity of the S(2P) antigen delivered by mRNA was confirmed 
in vitro before vaccination of the first human participant (Extended 
Data Fig. 3), and immunogenicity of mRNA-1273 was documented in 







































































































Fig. 1 | MERS-CoV S-2P mRNA protects mice from lethal challenge.  
a–d, 288/330+/+ mice were immunized at weeks 0 and 3 with 0.01 (green), 0.1 
(blue) or 1 μg (red) MERS-CoV S(2P) mRNA. Control mice were administered 
phosphate-buffered saline (PBS) (grey). a, Two weeks post-boost, sera were 
collected from three mice per group and assessed for neutralizing antibodies 
against MERS m35c4 pseudovirus. b–d, Four weeks post-boost, 12 mice per 
group were challenged with a lethal dose of mouse-adapted MERS-CoV 
(m35c4). b, Following challenge, mice were monitored for weight loss. c, d, Two 
days post-challenge, at peak viral load, lung viral titres (c) and haemorrhage 
(scored as: 0, no haemorrhage, 4, severe haemorrhage in all lobes) (d) were 
assessed from five mice per group. In c, d, all dose levels were compared by 
Kruskal–Wallis analysis of variance (ANOVA) with Dunn’s multiple comparisons 
test. In b, for weight loss, all comparisons are with PBS control mice at the same 
time point by two-sided Mann–Whitney U-test. **P < 0.01, ****P < 0.0001. Data 
are GMT ± geometric s.d. (a, c) or mean ± s.d. (b, d). In c, the dotted line 













































































































































































Fig. 2 | mRNA-1273 elicits robust binding and 
pseudovirus-neutralizing antibody responses in 
multiple mouse strains. a–f, BALB/cJ (a, d), C57BL/6J 
(b, e) or B6C3F1/J (c, f) mice (n = 10 per group) were 
immunized at weeks 0 and 3 with 0.01 (green), 0.1 
(blue) or 1 μg (red) mRNA-1273. Control BALB/cJ mice 
were administered PBS (grey). Sera were collected  
2 weeks post-prime (unfilled circles) and 2 weeks 
post-boost (filled circles) and assessed for SARS-CoV-2 
S-specific IgG by enzyme-linked immunosorbent assay 
(ELISA) (a–c), and for post-boost sera, neutralizing 
antibodies against homotypic SARS-CoV-2 
pseudovirus (d–f). In a–c, time points were compared 
within each dose level by two-sided Wilcoxon 
signed-rank test, and doses were compared post-boost 
by Kruskal–Wallis ANOVA with Dunn’s multiple 
comparisons test. In d–f, Vaccine groups were 
compared by two-sided Mann–Whitney U-test. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data 
are presented as GMT ± geometric s.d. Dotted lines 
represent assay limits of detection.
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Immunogenicity was assessed in six-week-old female BALB/cJ, 
C57BL/6J and B6C3F1/J mice by two intramuscular immunizations 
with 0.01, 0.1 or 1 μg mRNA-1273, separated by a 3-week interval. 
mRNA-1273 induced dose-dependent specific S-binding antibod-
ies after prime and boost in all mouse strains (Fig. 2a–c). Potent 
pseudovirus-neutralizing activity was elicited by 1 μg mRNA-1273, 
reaching reciprocal half-maximal inhibitory concentration (IC50) 
geometric mean titres (GMTs) of 819 (BALB/cJ), 89 (C57BL/6J) and 
1,115 (B6C3F1/J) (Fig. 2d–f). Additionally, mice immunized with 1 μg 
mRNA-1273 had robust neutralizing antibodies against pseudovi-
ruses that express S protein with the D614G substitution; SARS-CoV-2 
expressing the D614G variant of the S protein has recently become 
dominant around the world2 (Extended Data Fig. 4). To further gauge 
immunogenicity across a wide dose range, BALB/c mice were immu-
nized with 0.0025–20 μg mRNA-1273, revealing a strong positive cor-
relation between dose-dependent mRNA-1273-elicited binding and 
pseudovirus-neutralizing antibody responses (Extended Data Fig. 5). 
BALB/cJ mice that received a single dose of mRNA-1273 were evaluated 
to ascertain the utility of a single-dose vaccine. S-binding antibod-
ies were induced in mice immunized with one 1 μg or 10 μg dose of 
mRNA-1273. The 10 μg dose elicited pseudovirus-neutralizing antibody 
activity that increased between week 2 and week 4, reaching 315 recip-
rocal IC50 GMT (Extended Data Fig. 6a, b). These data demonstrate that 
mRNA expressing SARS-CoV-2 S(2P) is a potent immunogen and that 
pseudovirus-neutralizing activity can be elicited with a single dose.
Vaccine-associated enhanced respiratory disease (VAERD) has been 
associated with T helper 2 cell (TH2)-biased immune responses in chil-
dren immunized with whole-inactivated-virus vaccines against RSV 
and measles virus26,27. A similar phenomenon has also been reported in 
some animal models with whole-inactivated vaccines and other types 
of experimental SARS-CoV vaccines28–30. We therefore evaluated the 
balance of TH1 and TH2 cells in immunized mice. We first compared 
levels of S-specific immunoglobulins, IgG2a and IgG2c, and IgG1—
which are surrogates of TH1 and TH2 responses, respectively—elicited 
by mRNA-1273 with those elicited by immunization with SARS-CoV-2 
S(2P) protein using the TLR4 agonist Sigma Adjuvant System (SAS). 
Both immunogens elicited S-binding antibodies in the IgG2a and 
IgG1 subclasses, indicating a balanced TH1–TH2 response (Fig. 3a–c, 
Extended Data Fig. 7). The S-specific IgG-subclass profile following a 
single dose of mRNA-1273 (Extended Data Fig. 6c) was similar to that 
observed following two doses. By contrast, TH2-biased responses, 
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Fig. 3 | Immunizations with mRNA-1273 and S(2P) protein, delivered with 
TLR4 agonist, elicit S-specific TH1-biased T cell responses. B6C3F1/J mice 
(n = 10 per group) were immunized at weeks 0 and 3 with 0.01, 0.1 or 1 μg of 
mRNA-1273 or SARS-CoV-2 S(2P) protein with SAS adjuvant. a–c, Sera were 
collected two weeks post-boost and assessed by ELISA for SARS-CoV-2 
S-specific IgG1, and IgG2a and IgG2c. End-point titres (a, b) and end-point titre 
ratios of IgG2a plus IgG2c to IgG1 (c) were calculated. Ratios were not 
calculated for mice for which end-point titres did not reach the lower limit of 
detection (dotted line; N/A). d–g, Seven weeks post-boost, splenocytes were 
isolated from five mice per group and restimulated with vehicle or pools of 
overlapping peptides from SARS-CoV-2 S protein in the presence of a protein 
transport inhibitor cocktail. After 6 h, intracellular cytokine staining was 
performed to quantify CD4+ and CD8+ T cell responses. Cytokine expression in 
the presence of vehicle only was considered as background and subtracted 
from the responses measured from the S1 and S2 peptide pools for each 
individual mouse. d, e, Percentage of CD4+ T cells expressing IFN-γ, TNF, IL-2,  
IL-4 and IL-5 in response to the S1 (d) and S2 (e) peptide pools. f, g, Percentage of 
CD8+ T cells expressing IFN-γ, TNF and IL-2 in response to the S1 (f) and S2 (g) 
peptide pools.
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SARS-CoV-2 S(2P) protein formulated in alum (Extended Data Fig. 8a, b). 
Following restimulation with peptide pools (one pool of overlapping 
peptides for each S subunit, S1 and S2) covering the entire S protein, 
splenocytes from mice immunized with mRNA-1273 secreted more 
IFN-γ (a prototypic TH1 cytokine) than IL-4, IL-5 or IL-13 (classical TH2 
cytokines), whereas restimulation with SARS-CoV-2 S(2P) protein with 
alum adjuvant induced a TH2-biased response (Extended Data Fig. 8c, d). 
We also directly measured cytokine patterns in vaccine-induced mem-
ory T cells by intracellular cytokine staining seven weeks after the boost 
injection; mRNA-1273-elicited CD4+ T cells re-stimulated with S1 or 
S2 peptide pools exhibited a TH1-dominant response, particularly at 
higher immunogen doses (Fig. 3d, e). Furthermore, 1 μg mRNA-1273 
induced a robust CD8+ T cell response to the S1 peptide pool (Fig. 3f, g). 
Together, the IgG subclass and T cell cytokine data demonstrate that 
immunization with mRNA-1273 elicits balanced TH1 and TH2 responses, 
in contrast to the TH2-biased response seen when using S protein with 
alum adjuvant, suggesting that mRNA vaccination avoids TH2-biased 
immune responses, which have been linked to VAERD.
Protective immunity was assessed in young adult BALB/cJ mice 
challenged with mouse-adapted (MA) SARS-CoV-2. SARS-CoV-2 MA 
contains the substitutions Q498Y/P499T in the receptor-binding 
domain31. The substitutions enable the virus to bind to the mouse 
angiotensin-converting enzyme 2 (ACE2) receptor and infect and 
replicate in the upper and lower respiratory tract32. BALB/cJ mice that 
received two 1 μg doses of mRNA-1273 were completely protected from 
viral replication in lungs after challenge 5 or 13 weeks after boost injec-
tion (Fig. 4a, Extended Data Fig. 9a). mRNA-1273-induced immunity also 
resulted in undetectable viral replication in nasal turbinates in 6 out of 
7 mice (Fig. 4b, Extended Data Fig. 9b). The efficacy of mRNA-1273 was 
dose-dependent; two 0.1 μg doses of mRNA-1273 reduced lung viral 
load by about 100-fold, whereas two 0.01 μg doses reduced lung viral 
load by about 3-fold (Fig. 4a). Of note, mice challenged 7 weeks after 
a single dose of 1 or 10 μg mRNA-1273 were also completely protected 
against lung viral replication (Fig. 4c). Challenging animals immunized 
with subprotective doses provides an orthogonal assessment of safety 
signals such as increased clinical illness or pathology. Similar observa-
tions with MERS-CoV S(2P) mRNA, mice immunized with subprotective 
0.1 or 0.01 μg doses of mRNA-1273 showed no evidence of enhanced 
lung pathology or excessive mucus production (Fig. 4d). In summary, 
mRNA-1273 is immunogenic, efficacious and does not produce evidence 
of VAERD when given at subprotective doses in mice.
Here we have shown that 1 μg of mRNA-1273 is sufficient to induce 
robust pseudovirus-neutralizing activity and CD8 T cell responses, 
balanced TH1–TH2 antibody isotype responses, and protection from 
viral replication for more than three months following a prime–
boost regimen similar to the one being tested in humans. The level of 
pseudovirus-neutralizing activity induced by 1 μg mRNA-1273 in mice is 
similar in magnitude to that induced by 100 μg mRNA-1273 in humans33, 
which is the dose selected for mRNA-1273 to advance into phase III 
clinical trials. The inclusion of lower subprotective doses demonstrates 
the dose-dependence of antibody, TH1 CD4 T cell responses and protec-
tion, suggesting that immune correlates of protection can be further 
elucidated. Animal studies supporting candidate SARS-CoV-2 vaccines 
through clinical trials aim to demonstrate elicitation of potent protec-
tive immune responses as well as to show that subprotective responses 
do not cause VAERD5. Subprotective doses of mRNA-1273 did not prime 
mice for enhanced immunopathology following challenge. Moreover, 
the induction of protective immunity following a single dose suggests 
single-dose administration of this vaccine could be considered in the 
outbreak setting. These data, combined with immunogenicity data 
from non-human primates and human participants of early phase I 
clinical trials, have been used to inform the dose and regimen of mRNA-
1273 in advanced clinical efficacy trials.
The COVID-19 pandemic of 2020 is the widely predicted ‘pathogen X 
event’13,14. Here we provide a paradigm for rapid vaccine development. 
Combining structure-guided stabilization of the MERS-CoV S protein 
with a fast, scalable and safe mRNA–LNP vaccine platform has led to a 
generalizable vaccine solution for Betacoronavirus and a commercial 
mRNA vaccine delivery platform; these developments enabled a rapid 
response to the COVID-19 outbreak. This response demonstrates how 
new technology-driven concepts such as synthetic vaccinology can 
facilitate a vaccine development programme initiated on the basis of 















































































































Fig. 4 | mRNA-1273 protects mice from upper- and lower-airway SARS-CoV-2 
infection. a, b, BALB/cJ mice (n = 10 per group) immunized at weeks 0 and 3 
with 0.01 μg (green), 0.1 μg (blue) or 1 μg (red) mRNA-1273 or PBS were 
challenged with SARS-CoV-2 MA five weeks post-boost. c, Other groups were 
immunized with single doses of 0.1 μg (blue), 1 μg (red) or 10 μg (purple) 
mRNA-1273 and challenged 7 weeks after immunization. Two days after 
challenge, at peak viral load, mouse lungs (a, c) and nasal turbinates (b) were 
collected from five mice per group to measure viral titres. a–c, Data are 
presented as GMT ± geometric s.d. and dotted lines represent assay limits of 
detection. Group comparisons were made by Kruskal–Wallis ANOVA with 
Dunn’s multiple comparisons test. **P < 0.01, ***P < 0.001. d, At days 2 and 4 
after challenge, lung sections from 5 mice per group were stained with 
haematoxylin and eosin, and representative photomicrographs (original 
magnification ×4 (scale bars, 600 μm) and ×10 (scale bars, 300 μm) as 
indicated) from each group with detectable virus in lung are shown. Day 2 lungs 
from PBS control mice demonstrated moderate-to-severe, predominantly 
neutrophilic inflammation present within and surrounding small bronchioles 
(arrowheads); alveolar capillaries were markedly expanded by infiltrating 
inflammatory cells. In the 0.01 μg two-dose group, inflammation was minimal 
to absent. In the 0.1 μg two-dose group, occasional areas of inflammation 
intimately associated with small airways (bronchioles) and adjacent 
vasculature (arrowheads) were seen, primarily composed of neutrophils. In the 
single-dose 0.1 μg group, there were mild patchy expansions of alveolar septae 
by mononuclear and polymorphonuclear cells. At day 4, lungs from PBS control 
mice exhibited moderate-to-marked expansion of alveolar septae (interstitial 
pattern) with decreased prominence of adjacent alveolar spaces. In the 0.01 μg 
two-dose group, inflammation was minimal to absent. Lungs in the 0.1 μg 
two-dose group showed mild, predominantly lymphocytic inflammation, 
associated with bronchioles and adjacent vasculature (arrowheads). In the 
single-dose 0.1 μg group there was mild, predominantly lymphocytic 
inflammation around bronchovascular bundles (arrowheads).
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pathogen sequences alone11. This study also provides a proof of concept 
for the prototype-pathogen approach to pandemic preparedness and 
response that is predicated on identifying generalizable solutions for 
medical counter measures within virus families or genera13. Although 
the response to the COVID-19 pandemic has been unprecedented in 
its speed and breadth, we envision further improvements in rapid 
responses to such threats. There are 24 other virus families that are 
known to infect humans, and sustained investigation of those potential 
threats will improve our readiness for future pandemics14.
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No statistical methods were used to predetermine sample size. The 
experiments were not randomized. The investigators were not blinded 
to allocation during experiments and outcome assessment.
Pre-clinical mRNA-1273 mRNA and LNP production process
A sequence-optimized mRNA encoding SARS-CoV-2 S(2P) protein was 
synthesized in vitro using an optimized T7 RNA polymerase-mediated 
transcription reaction with complete replacement of uridine by 
N1-methyl-pseudouridine34. The reaction included a DNA template 
containing the immunogen open reading frame flanked by 5′ untrans-
lated region (UTR) and 3′ UTR sequences and was terminated by an 
encoded polyA tail. After transcription, the Cap 1 structure was added 
to the 5′ end using vaccinia capping enzyme (New England Biolabs) and 
Vaccinia 2′ O-methyltransferase (New England Biolabs). The mRNA 
was purified by oligo-dT affinity purification, buffer exchanged by 
tangential flow filtration into sodium acetate, pH 5.0, sterile filtered, 
and kept frozen at –20 °C until further use.
The mRNA was encapsulated in a lipid nanoparticle through a modi-
fied ethanol-drop nanoprecipitation process as described previously20. 
In brief, ionizable, structural, helper and polyethylene glycol lipids 
were mixed with mRNA in acetate buffer, pH 5.0, at a ratio of 2.5:1 
(lipids:mRNA). The mixture was neutralized with Tris-Cl pH 7.5, sucrose 
was added as a cryoprotectant, and the final solution was sterile filtered. 
Vials were filled with formulated LNP and stored frozen at –70 °C until 
further use. The drug product underwent analytical characterization, 
which included the determination of particle size and polydispersity, 
encapsulation, mRNA purity, double stranded RNA content, osmolality, 
pH, endotoxin and bioburden, and the material was deemed accept-
able for in vivo study.
MERS-CoV and SARS-CoV protein expression and purification
Vectors encoding MERS-CoV S-2P1 and SARS-CoV S-2P23 were generated 
as previously described with the following small amendments. Proteins 
were expressed by transfection of plasmids into Expi293 cells using 
Expifectamine transfection reagent (ThermoFisher) in suspension 
at 37 °C for 4–5 days. Transfected cell culture supernatants were col-
lected, buffer exchanged into 1× PBS, and protein was purified using 
Strep-Tactin resin (IBA). For proteins used for mouse inoculations, tags 
were cleaved with addition of HRV3C protease (ThermoFisher) (1% wt/wt) 
overnight at 4 °C. Size-exclusion chromatography using Superose 6 
Increase column (GE Healthcare) yielded final purified protein.
Design and production of recombinant minifibritin foldon 
protein
A mammalian codon-optimized plasmid encoding foldon inserted 
minifibritin (ADIVLNDLPFVDGPPAEGQSRISWIKNGEEILGADTQYGSE 
GSMNRPTVSVLRNVEVLDKNIGILKTSLETANSDIKTIQEAGYIPEAPRDGQA 
YVRKDGEWVLLSTFLSPALVPRGSHHHHHHSAWSHPQFEK) with a 
C-terminal thrombin cleavage site, 6×His tag, and Strep-TagII was syn-
thesized and subcloned into a mammalian expression vector derived 
from pLEXm. The construct was expressed by transient transfection of 
Expi293 (ThermoFisher) cells in suspension at 37 °C for 5 days. The pro-
tein was first purified with a Ni2+-nitrilotriacetic acid resin (GE Health-
care) using an elution buffer consisting of 50 mM Tris-HCl, pH 7.5, 400 
mM NaCl and 300 mM imidazole pH 8.0, followed by purification with 
StrepTactin resin (IBA) according to the manufacturer’s instructions.
Cell lines
HEK293T/17 (ATCC CRL-11268), Vero E6 (ATCC), Huh7.5 cells (provided 
by D. R. Taylor, US Food and Drug Administration) and ACE2-expressing 
293T cells (provided by M. Farzan, Scripps Research Institute) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% FBS, 2 mM glutamine and 1% penicillin–streptomycin at 37 °C 
and 5% CO2. Vero E6 cells used in plaque assays to determine lung and 
nasal turbinate viral titres were cultured in DMEM supplemented with 
10% Fetal Clone II and 1% antibiotic–antimycotic at 37 °C and 5% CO2. 
Vero E6 cells used in plaque-reduction neutralization test (PRNT) 
assays were cultured in DMEM supplemented with 10% Fetal Clone II 
and amphotericin B (0.25 μg ml−1) at 37 °C and 5% CO2. Lentivirus encod-
ing hACE2-P2A-TMPRSS2 was made to generate A549-hACE2-TMPRSS2 
cells, which were maintained in DMEM supplemented with 10% FBS 
and 1 μg ml−1 puromycin. Expi293 cells were maintained in the manu-
facturer’s suggested medium. BHK-21/WI-2 cells were obtained from 
Kerafast and cultured in DMEM with 5% FBS at 37 °C and 6–8% CO2. Cell 
lines were not authenticated. All cells lines were tested for mycoplasma 
and remained negative.
In vitro mRNA expression
HEK293T cells were transiently transfected with mRNA encoding 
SARS-CoV-2 wild-type S or S(2P) protein using a TranIT mRNA trans-
fection kit (Mirus). After 24 h, the cells were collected and resuspended 
in fluorescence-activated cell sorting (FACS) buffer (1× PBS, 3% FBS, 
0.05% sodium azide). To detect surface-protein expression, the cells 
were stained with 10 μg ml−1 ACE2–Flag (Sigma) or 10 μg ml−1 CR302235 
in FACS buffer for 30 min on ice. Thereafter, cells were washed twice in 
FACS buffer and incubated with FITC–anti-Flag (Sigma) or Alexa Fluor 
647–goat anti-human IgG (Southern Biotech) in FACS buffer for 30 min 
on ice. Live/Dead aqua fixable stain (Invitrogen) were used to assess 
viability. Data acquisition was performed on a BD LSRII Fortessa instru-
ment (BD Biosciences) and analysed by FlowJo software v.10 (Tree Star).
Mouse models
Animal experiments were carried out in compliance with all perti-
nent US National Institutes of Health regulations and approval from 
the Animal Care and Use Committee (ACUC) of the Vaccine Research 
Center, Moderna Inc., or University of North Carolina at Chapel Hill. 
For immunogenicity studies, 6- to 8-week-old female BALB/c (Charles 
River), BALB/cJ, C57BL/6J or B6C3F1/J mice ( Jackson Laboratory) were 
used. mRNA formulations were diluted in 50 μl 1× PBS, and mice were 
inoculated intramuscularly in the same hind leg for both prime and 
boost. Control mice received PBS because previous studies have 
demonstrated the mRNA formulations being tested do not create 
substantial levels of nonspecific immunity beyond a few days36–38. 
For all SARS-CoV-2 S(2P) protein vaccinations, mice were inoculated 
intramuscularly with SAS as previously described1. For S(2P) + alum 
immunizations, SARS-CoV-2 S(2P) protein + 250 μg alum hydrogel was 
delivered intramuscularly. For challenge studies to evaluate MERS-CoV 
vaccines, 16- to 20-week-old male and female 288/330+/+mice22 were 
immunized. Four weeks post-boost, pre-challenge sera were collected 
from a subset of mice, and the remaining mice were challenged with 
5 × 105 PFU of a mouse-adapted MERS-CoV EMC derivative, m35c439. 
On day 3 post-challenge, lungs were collected and haemorrhage and 
viral titre were assessed according to previously published methods40. 
For challenge studies to evaluate SARS-CoV-2 vaccines, BALB/cJ mice 
were challenged with 105 PFU SARS-CoV-2 MA. This virus contains two 
mutations (Q498T/P499Y) in the receptor binding domain that enable 
binding of SARS-CoV-2 S protein to the mouse ACE2 receptor and infec-
tion and replication in the upper and lower respiratory tract32. On day 
2 post-challenge, lungs and nasal turbinates were collected for viral 
titre assessment according to previously published methods32. Sample 
size for animal experiments was determined on the basis of criteria set 
by institutional ACUC. Experiments were not randomized or blinded.
Histology
Lungs were collected from mice at the indicated study end points and 
placed in 10% neutral-buffered formalin until adequately fixed. Thereafter, 
tissues were trimmed to a thickness of 3–5 mm, processed and paraffin 
embedded. The respective paraffin tissue blocks were sectioned at 5 μm 
and stained with haematoxylin and eosin. All sections were examined by a 
board-certified veterinary pathologist using an Olympus BX51 light micro-
scope, and photomicrographs were taken using an Olympus DP73 camera.
ELISA
Nunc Maxisorp ELISA plates (ThermoFisher) were coated with 100 ng 
per well of protein in 1× PBS at 4 °C for 16 h. Where applicable, to elimi-
nate fold-on-specific binding from MERS-CoV S(2P) or SARS-CoV-2 S(2P) 
protein-immune mouse serum, 50 μg ml−1 of fold-on protein was added 
for 1 h at room temperature. After standard washes and blocks, plates 
were incubated with serial dilutions of heat-inactivated sera for 1 h at 
room temperature. Following washes, anti-mouse IgG, IgG1 or IgG2a 
and/or IgG2c–horseradish peroxidase conjugates (ThermoFisher) 
were used as secondary antibodies, and 3,5,3′5′-tetramethylbenzidine 
(TMB) (KPL) was used as the substrate to detect antibody responses. 
End-point titres were calculated as the dilution that emitted an optical 
density exceeding 4× background (secondary antibody alone).
Lentivirus-based pseudovirus-neutralization assay
The pseudovirus-neutralization assay measures the inhibition of pseu-
dovirus attachment and entry including fusion-inhibiting activity. It is 
a single-round virus, does not replicate, and does not express the S pro-
tein in transduced cells. Therefore, pseudovirus infection will not cause 
cell-to-cell fusion or plaque formation that can be measured in a classi-
cal neutralization assay using live virus. This pseudovirus neutralization 
assay has been shown to correlate with live virus plaque-reduction 
neutralization33, and because it does not require BL3 containment, was 
chosen as the preferred assay for measuring neutralizing activity in 
these studies. We introduced divergent amino acids, as predicted from 
translated sequences, into the CMV/R-MERS-CoV EMC S (GenBank: 
AFS88936) gene41 to generate a MERS-CoV m35c4 S gene39. To produce 
SARS-CoV-2 pseudoviruses, a codon-optimized CMV/R-SARS-CoV-2 
S (Wuhan-1, GenBank: MN908947.3) plasmid was constructed. Pseu-
doviruses were produced by co-transfection of plasmids encoding a 
luciferase reporter, lentivirus backbone, and S genes into HEK293T/17 
cells (ATCC CRL-11268), as previously described41. For SARS-CoV-2 pseu-
dovirus, human transmembrane protease serine 2 (TMPRSS2) plasmid 
was also co-transfected42. Pseudoneutralization assay methods have 
been previously described1,33. In brief, heat-inactivated serum was 
mixed with pseudoviruses, incubated, and then added to Huh7.5 cells 
or ACE-2-expressing 293T cells for MERS-CoV and SARS-CoV-2 respec-
tively. Seventy-two hours later, cells were lysed and luciferase activity 
(in relative light units (RLU)) was measured. Per cent neutralization 
was normalized considering uninfected cells as 100% neutralization 
and cells infected with only pseudovirus as 0% neutralization. IC50 
titres were determined using a log (agonist) vs normalized-response 
(variable slope) nonlinear function in Prism v8 (GraphPad).
Recombinant VSV∆G-based pseudovirus neutralization assay
Codon-optimized wild-type (D614) or D614G spike gene (Wuhan-Hu-1 
strain, NCBI reference sequence: NC_045512.2) was cloned into pCAGGS 
vector. To generate VSV∆G-based SARS-CoV-2 pseudovirus, BHK-21/WI-2 
cells were transfected with the spike expression plasmid and infected 
VSV∆G-firefly-luciferase as previously described43. A549-hACE2-TMPRSS2 
cells were infected by pseudovirus for 1 h at 37 °C. The inoculum virus or 
virus-antibody mix was removed after infection. Eighteen hours later, an 
equal volume of One-Glo reagent (Promega) was added to culture medium 
for readout using a BMG PHERastar-FS plate reader. The neutralization 
procedure and data analysis are the same as mentioned above for the 
lentivirus-based pseudovirus neutralization assay.
PRNT assays
Heat-inactivated sera were diluted in gelatin saline (0.3% (wt/vol) gelatin 
in PBS supplemented with CaCl2 and MgCl2 to generate a 1:5 dilution 
of the original specimen, which served as a starting concentration for 
further serial log4 dilutions terminating in 1:81,920. Sera were com-
bined with an equal volume of SARS-CoV-2 clinical isolate 2019-nCoV 
USA-WA1-F6/2020 in gelatin saline, resulting in an average concentra-
tion of 730 PFU per ml (determined from plaque counts of 24 individual 
wells of untreated virus) in each serum dilution. Thus, final serum con-
centrations ranged from 1:10 to 1:163,840 of the original. Virus–serum 
mixtures were incubated for 20 min at 37 °C, followed by adsorption 
of 0.1 ml to each of two confluent Vero E6 cell monolayers (in 10 cm2 
wells) for 30 min at 37 °C. Cell monolayers were overlaid with DMEM 
containing 1% agar and incubated for 3 d at 37 °C in humidified 5% CO2. 
Plaques were enumerated by direct visualization. The average number 
of plaques in virus + serum (duplicate) and virus-only (24 repeats) wells 
was used to generate percent neutralization curves according the fol-
lowing formula: 1 – (ratio of mean number of plaques in the presence 
and absence of serum). The PRNT IC50 titre was defined as the recipro-
cal serum dilution at which the neutralization curve crossed the 50% 
threshold.
Intracellular cytokine staining
Mononuclear single-cell suspensions from whole mouse spleens were 
generated using a gentleMACS tissue dissociator (Miltenyi Biotec) fol-
lowed by 70-μm filtration and density gradient centrifugation using 
Fico/Lite-LM medium (Atlanta Biologicals). Cells from each mouse 
were resuspended in R10 media (RPMI 1640 supplemented with penicil-
lin–streptomycin antibiotic, 10% heat-inactivated FBS, Glutamax and 
HEPES) and incubated for 6 h at 37 °C with protein transport inhibitor 
cocktail (eBioscience) under three conditions: no peptide stimula-
tion, and stimulation with two S-protein peptide pools ( JPT product 
PM-WCPV-S-1). Peptide pools were used at a final concentration of 2 
μg ml per peptide. Cells from each group were pooled for stimulation 
with cell stimulation cocktail (eBioscience) as a positive control. Fol-
lowing stimulation, cells were washed with PBS before staining with 
LIVE/DEAD Fixable Blue Dead Cell Stain (Invitrogen, L23105; 1:800) 
for 20 min at room temperature. Cells were then washed in FC buffer 
(PBS supplemented with 2% heat-inactivated FBS and 0.05% NaN3) and 
resuspended in Fc Block (BD, 553141, clone 2.4G2; 1:100) for 5 min at 
room temperature before staining with a surface stain cocktail contain-
ing the following antibodies: I-A/I-E PE (BD, 557000, clone M5/114.15.2; 
1:2,500), CD8a BUV805 (BD, 612898, clone 53-6.7; 1:80), CD44 BUV395 
(BD, 740215, clone IM7; 1:800), CD62L BV605 (Biolegend, 104418, clone 
MEL-14; 1:5,000) and CD4 BV480 (BD, 565634, clone RM4-5; 1:500) 
in brilliant stain buffer (BD). After 15 min, cells were washed with FC 
buffer then fixed and permeabilized using the BD Cytofix/Cytoperm 
fixation/permeabilization solution kit according to the manufacturer’s 
instructions. Cells were washed in perm/wash solution and stained with 
Fc Block (5 min at room temperature), followed by intracellular stain-
ing (30 min at 4 °C) using a cocktail of the following antibodies: CD3e 
BUV737 (BD, 741788, clone 17A2; 1:80), IFN-γ BV650 (BD, 563854, clone 
XMG1.2; 1:500), TNF BV711 (BD, 563944, clone MP6-XT22; 1:80), IL-2 
BV421 (BD, 562969, clone JES6-5H4; 1:80), IL-4 Alexa Fluor 488 (Bioleg-
end, 504109, clone 11B11; 1:80) and IL-5 APC (Biolegend, 504306, clone 
TRFK5; 1:320) in 1× perm/wash diluted with brilliant stain buffer. Finally, 
cells were washed in perm/wash solution and resuspended in 0.5% 
PFA–FC stain buffer before running on a Symphony A5 flow cytometer 
(BD). Analysis was performed using FlowJo software, v.10.6.2 according 
to the gating strategy outlined in Extended Data Fig. 10. Background 
cytokine expression in the no-peptide condition was subtracted from 
that measured in the S1 and S2 peptide pools for each individual mouse.
T cell stimulation and cytokine analysis
Spleens from immunized mice were collected two weeks post-boost. 
Two-million splenocytes per well (96-well plate) were stimulated 
in vitro with two peptide libraries, JPT1 and JPT2, (15mers with 11 amino 
acid overlap) covering the entire SARS-CoV-2 S protein ( JPT product 
Article
PM-WCPV-S-1). Both peptide libraries were used at a final concentration 
of 1 μg ml−1. After 24 h of culture at 37 °C, the plates were centrifuged 
and supernatant was collected and frozen at −80 °C for cytokine detec-
tion. Measurements and analyses of secreted cytokines from a murine 
35-plex kit were performed using a multiplex bead-based technology 
(Luminex) assay with a Bio-Plex 200 instrument (Bio-Rad) after twofold 
dilution of supernatants.
Statistical analysis
Geometric means or arithmetic means are represented by the heights of 
bars, or symbols, and error bars represent the corresponding s.d. Dot-
ted lines indicate assay limits of detection. Two-sided Mann–Whitney 
U-tests were used to compare two experimental groups and two-sided 
Wilcoxon signed-rank tests to compare the same animals at different 
time points. To compare more than two experimental groups, Kruskal–
Wallis ANOVA with Dunn’s multiple comparisons tests were applied. In 
Extended Data Fig. 5a, b, all doses were compared to the 20 μg dose by 
two-sided Mann–Whitney U-test in a stepwise fashion, such that lowest 
doses were tested first at α = 0.05 and higher doses were tested only 
if the lower doses were significant. In Extended Data Fig. 5c, a Spear-
man correlation test was used to correlate binding antibody titres to 
pseudovirus-neutralizing antibody titres. Statistical analyses were 
performed using R v.4.0.0 or Prism v.8 (GraphPad). *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The authors declare that the data supporting the findings of this 
study are available within this Article and its Supplementary Infor-
mation. Source data are provided with this paper.
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Extended Data Fig. 1 | Transmembrane-anchored MERS-CoV S-2P (S-2P_TM) 
mRNA elicits more potent pseudovirus neutralizing antibody responses 
than secreted MERS-CoV S(2P) and S WT mRNA. a, b, C57BL/6J mice (n = 10/
group) were immunized at weeks 0 and 4 with (a) 0.4, 2, or 10 μg of MERS-CoV 
S-2P_TM (red) or MERS S-2P_secreted (red hashed) or (b) 0.016 μg, 0.08 μg, or 
0.4 μg of MERS-CoV S(2P) or MERS-CoV S WT_TM (black) mRNA. Sera were 
collected 4 weeks post-boost and assessed for neutralizing antibodies against 
MERS-CoV m35c4 pseudovirus. Immunogens were compared at each dose level 
by two-sided Mann–Whitney U-test. *P < 0.05, ****P < 0.0001. Data are 
presented as GMT ± geometric s.d.
Article
Extended Data Fig. 2 | Timeline for mRNA-1273’s progression to clinical 
trial. The morning after novel coronavirus (nCoV) sequences were released, 
spike sequences were modified to include prefusion stabilizing mutations and 
synthesized for protein production, assay development, and vaccine 
development. Twenty-five days after viral sequences were released, 
clinically-relevant mRNA-1273 was received to initiate animal experiments. 
Immunogenicity in mice was confirmed 15 days later. Moderna shipped clinical 
drug product 41 days after GMP production began, leading to the phase I 
clinical trial starting 66 days following the release of nCoV sequences.
Extended Data Fig. 3 | In vitro expression of SARS-CoV-2 spike mRNA on 
the cell surface. a–d, 293T cells were transfected in duplicate with mRNA 
expressing SARS-CoV-2 wild-type spike (white bars, black lines) or S-2P (red), 
stained with ACE2 (a, c) or CR3022 (b, d), and evaluated by flow cytometry 24 
post-transfection. Mock-transfected (PBS) cells served as a control (grey).  
(a, b) Data are presented as mean.
Article
Extended Data Fig. 4 | mRNA-1273 elicits robust pseudovirus neutralizing 
antibody responses to SARS-CoV-2_D614G. BALB/c mice (n = 24) were 
immunized at weeks 0 and 3 weeks with 1 μg (red) of mRNA-1273, in three 
individual studies (n = 8/study). Sera were collected 2 weeks post-boost and 
assessed for neutralizing antibodies against homotypic SARS-CoV-2_D614 
pseudovirus (circles) or SARS-CoV-2_D614G (squares). Comparisons between 
D614 and D614G were made by two-sided Wilcoxon signed rank test. *P < 0.05.
Extended Data Fig. 5 | Dose-dependent mRNA-1273-elicited antibody 
responses reveal strong positive correlation between binding and 
pseudovirus neutralization titres. a–c, BALB/c mice (n = 10/group) were 
immunized at weeks 0 and 3 weeks with various doses (0.0025–20 μg) of 
mRNA-1273. Sera were collected 2 weeks post-boost and assessed for 
SARS-CoV-2 S-specific IgG by ELISA (a) and neutralizing antibodies against 
homotypic SARS-CoV-2 pseudovirus (b). a, b, All doses were compared to the 
20 μg dose by two-sided Mann–Whitney U-test in a stepwise fashion, such that 
lowest doses were tested first at α = 0.05 and higher doses tested only if the 
lower doses were significant. Data are presented as GMT ± geometric s.d., and 
dotted lines represent assay limits of detection. c, Spearman correlation test 
was used to correlate binding antibody titres to pseudovirus neutralizing 
antibody titres (P < 0.0001). Each dot represents an individual mouse. Dotted 
lines highlight log10 IC50 boundaries. **P < 0.01, ***P < 0.001.
Article
Extended Data Fig. 6 | A single dose of mRNA-1273 elicits robust antibody 
responses. a–c, BALB/cJ mice (n = 10/group) were immunized with 0.01 
(green), 0.1 (blue), 1 μg (red), or 10 μg (purple) of mRNA-1273. Sera were 
collected 2 (unfilled circles) and 4 (filled circles) weeks post-immunization and 
assessed for SARS-CoV-2 S-specific total IgG by ELISA (a) and neutralizing 
antibodies against homotypic SARS-CoV-2 pseudovirus (b). c, S-specific IgG2a 
and IgG1 were also measured by ELISA, and IgG2a to IgG1 subclass ratios were 
calculated. In a, b, Time points were compared within each dose level by 
two-sided Wilcoxon signed-rank test, and doses were compared 4 weeks 
post-boost by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons test.  
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. c, Doses were compared by 
two-sided Mann–Whitney U-test, and no significance was found. Data are 
presented as GMT ± geometric s.d. (a, b) or mean ± s.d. (c), and dotted lines 
represent assay limits of detection.
Extended Data Fig. 7 | mRNA-1273 and SAS-adjuvanted S-2P protein elicit 
both IgG2a and IgG1 subclass S-binding antibodies. a–f, BALB/cJ (a–c) or 
C57BL/6J (d–f) mice (n = 10/group) were immunized at weeks 0 and 3 with 0.01 
(green), 0.1 (blue), or 1 μg (red) of mRNA-1273 or SARS-CoV-2 S-2P protein 
adjuvanted with SAS. Sera were collected 2 weeks post-boost and assessed by 
ELISA for SARS-CoV-2 S-specific IgG1 and IgG2a or IgG2c for BALB/cJ and 
C57BL/6J mice, respectively. End-point titres (a, b, d, e) and end-point titre 
ratios of IgG2a to IgG1 (c) and IgG2c to IgG1 (f) were calculated. For mice for 
which end-point titres did not reach the lower limit of detection (dotted line), 
ratios were not calculated (N/A). Data are presented as GMT ± geometric s.d.  
(a, b, d, e) or mean ± s.d. (c, f).
Article
Extended Data Fig. 8 | mRNA-1273 elicits TH1-skewed responses compared 
to S-2P protein adjuvanted with alum. BALB/c mice (n = 6/group) were 
immunized at weeks 0 and 2 weeks with 1 (red) or 10 μg (purple) of mRNA-1273 
or 10 μg of SARS-CoV-2 S-2P protein adjuvanted with alum hydrogel (orange). 
Control mice were administered PBS (grey) (n = 3). a, b, Sera were collected  
2 weeks post-boost and assessed by ELISA for SARS-CoV-2 S-specific IgG1 and 
IgG2a. End-point titres (a) and end-point titre ratios of IgG2a to IgG1 (b) were 
calculated. c, d, Splenocytes were collected 4 weeks post-boost to evaluate 
IFN-γ, IL-4, IL-5, and IL-13 cytokine levels secreted by T cells re-stimulated with 
S1 (c) and S2 (d) peptide pools, measured by Luminex. In b, immunogens were 
compared by two-sided Mann–Whitney U-test. In c, d, for cytokines, all 
comparisons were compared to PBS control mice by Kruskal–Wallis ANOVA 
with Dunn’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001,  
****P < 0.0001. Data are presented as GMT ± geometric s.d. (a) or mean ± s.d.  
(b–d). Dotted line represents assay limit of detection.
Extended Data Fig. 9 | mRNA-1273 protects mice from upper- and 
lower-airway SARS-CoV-2 infection, 13 weeks post-boost. a, b, BALB/cJ mice 
were immunized at weeks 0 and 3 with 0.01 (green), 0.1 (blue), or 1 μg (red) of 
mRNA-1273. Age-matched naive mice (grey) served as controls. Thirteen weeks 
post-boost, mice were challenged with mouse-adapted SARS-CoV-2. Two days 
post-challenge, at peak viral load, mouse lungs (a) and nasal turbinates (b) were 
collected from 5 mice per group (3 mice for the 1 μg group) for analysis of viral 
titres. All dose levels were compared by Kruskal–Wallis ANOVA with Dunn’s 
multiple comparisons test. *P <  0.05. Data are presented as GMT ± geometric 
s.d. Dotted line represents assay limit of detection.
Article
Extended Data Fig. 10 | Flow cytometry panel to quantify SARS-CoV-2 
S-specific T cells in mice. a, Related to Fig. 3d–g, a hierarchical gating strategy 
was used to unambiguously identify single, viable CD4+ and CD8+ T cells.  
b–e, Gating summary of SARS-CoV-2 S-specific (b, c) CD4+ and (d, e) CD8+ T cells 
elicited by 0.01 and 1 μg mRNA-1273 immunization. Antigen-specific T cell 
responses following peptide pool re-stimulation were defined as CD44hi/
cytokine+. Concatenated files shown were generated using the same number of 
randomly selected events from each animal across the different stimulation 
conditions using FlowJo software, v.10.6.2.
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Sample size Sample size for animal experiments was determined based on criteria set by institutional ACUC. 
Data exclusions No data were excluded. 
Replication Animal studies were completed once. All immunoassay testing was completed in duplicate or triplicate with 1 replicate, unless otherwise 
stated. 
Randomization Allocation of animals was not random. 
Blinding Blinding was not completed as assays were completed by the same team that immunized animals. 
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Antibodies used CR3022 (made in house, citation below) | For ICS, a surface stain cocktail containing the following antibodies: I-A/I-E PE (BD, cat. 
557000, clone M5/114.15.2, 1/2500), CD8a BUV805 (BD, cat. 612898, clone 53-6.7, 1/80), CD44 BUV395 (BD, cat. 740215, clone IM7, 
1/800), CD62L BV605 (Biolegend, cat. 104418, clone MEL-14, 1/5000), and CD4 BV480 (BD, cat. 565634, clone RM4-5, 1/500)
Validation Jan ter Meulen, J. et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape 
Mutants. PLOS Medicine 3, e237, doi:10.1371/journal.pmed.0030237 (2006).
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Expi293 (ThermoFisher), HEK293T/17 (ATCC #CRL-11268), Vero E6 (ATCC), Huh7.5 cells (provided by Deborah R. Taylor, US 
Food and Drug Administration), ACE-2-expressing 293T (ATCC) cells (provided by Michael Farzan, Scripps Research Institute). 
Huh7.5 cells are a derivative of Huh7 cells (ATCC). 
Authentication Cell lines were not authenticated. 
Mycoplasma contamination All cells tested negative for mycoplasma.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines are in this study. 
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Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals 6-8-week-old female BALB/c (Charles River), BALB/cJ, C57BL/6J, or B6C3F1/J mice (Jackson Laboratory) | 16-20-week-old male and 
female 288/330+/+mice
Wild animals There were no wild animals used in this study
Field-collected samples There were no field-collected samples.
Ethics oversight Animal experiments were carried out in compliance with all pertinent US National Institutes of Health regulations and approval from 
the Animal Care and Use Committee of the Vaccine Research Center, Moderna Inc., or University of North Carolina at Chapel Hill. 




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Mononuclear single cell suspensions from whole mouse spleens were generated using a gentleMACS tissue dissociator 
(Miltenyi Biotec) followed by 70 μm filtration and density gradient centrifugation using Fico/Lite-LM medium (Atlanta 
Biologicals). Cells from each mouse were resuspended in R10 media (RPMI 1640 supplemented with Pen-Strep antibiotic, 
10% HI-FBS, Glutamax, and HEPES) and incubated for 6 hr at 37°C with protein transport inhibitor cocktail (eBioscience) 
under three conditions: no peptide stimulation, and stimulation with two spike peptide pools (JPT product PM-WCPV-S-1). 
Peptide pools were used at a final concentration of 2 μg/mL each peptide. Cells from each group were pooled for stimulation 
with cell stimulation cocktail (eBioscience) as a positive control. Following stimulation, cells were washed with PBS prior to 
staining with LIVE/DEAD Fixable Blue Dead Cell Stain (Invitrogen) for 20 min at RT. Cells were then washed in FC buffer (PBS 
supplemented with 2% HI-FBS and 0.05% NaN3) and resuspended in BD Fc Block (clone 2.4G2) for 5 min at RT prior to 
staining with a surface stain cocktail containing the following antibodies purchased from BD and Biolegend: I-A/I-E 
(M5/114.15.2) PE, CD8a (53-6.7) BUV805, CD44 (IM7) BUV395, CD62L (MEL-14) BV605, and CD4 (RM4-5) BV480 in brilliant 
stain buffer (BD). After 15 min, cells were washed with FC buffer then fixed and permeabilized using the BD Cytofix/Cytoperm 
fixation/permeabilization solution kit according to manufacturer instructions. Cells were washed in perm/wash solution and 
stained with Fc Block (5 min at RT), followed by intracellular staining (30 min at 4°C) using a cocktail of the following 
antibodies purchased from BD, Biolegend, or eBioscience: CD3e (17A2) BUV737, IFN-γ (XMG1.2) BV650, TNF-α (MP6-XT22) 
BV711, IL-2 (JES6-5H4) BV421, IL-4 (11B11) Alexa Fluor 488, and IL-5 (TRFK5) APC in 1x perm/wash diluted with brilliant stain 
buffer. Finally, cells were washed in perm/wash solution and resuspended in 0.5% PFA-FC stain buffer prior to running on a 
Symphony A5 flow cytometer (BD). Analysis was performed using FlowJo software, version 10.6.2 according to the gating 
strategy outlined in Extended Data Figure 9. Background cytokine expression in the no peptide condition was subtracted 
from that measured in the S1 and S2 peptide pools for each individual mouse.
Instrument Symphony A5 flow cytometer (BD)
Software FlowJo software, version 10.6.2
Cell population abundance Concatenated files shown were generated using the same number of randomly selected events from each animal across the 
different stimulation conditions. 
Gating strategy Extended Data Fig. 10 shows a hierarchical gating strategy was used to unambiguously identify single, viable CD4+ and CD8+ 
T cells. Gating summary of SARS-CoV-2 S-specific CD4  (b-c) and  CD8 (d-e) T cells. Antigen-specific T cell responses following 
peptide pool re-stimulation were defined as CD44hi/cytokine+. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
